2′-Carbohydrate modifications in antisense oligonucleotide therapy:: importance of conformation, configuration and conjugation

被引:318
作者
Manoharan, M [1 ]
机构
[1] ISIS Pharmaceut, Dept Med Chem, Carlsbad, CA 92008 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1999年 / 1489卷 / 01期
关键词
2 '-carbohydrate modification; antisense oligonucleotide therapy;
D O I
10.1016/S0167-4781(99)00138-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 2'-position of the carbohydrate moiety has proven to be a fertile position for oligonucleotide modifications for antisense technology. The 2'-modifications exhibit high binding affinity to target RNA, enhanced chemical stability and nuclease resistance and increased lipophilicity. All high binding affinity 2'-modifications have Cy-endo sugar pucker. In addition to gauche effects, charge effects are also important in determining the level of their nuclease resistance. Pharmacokinetic properties of oligonucleotides are altered by 2'-conjugates. For certain modifications (e.g., 2'-F), the configuration at the 2'-position, arabino vs. ribo, determines their ability to activate the enzyme RNase H. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:117 / 130
页数:14
相关论文
共 72 条
[1]   Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats [J].
Agrawal, S ;
Zhao, QY ;
Jiang, ZW ;
Oliver, C ;
Giles, H ;
Heath, J ;
Serota, D .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1997, 7 (06) :575-584
[2]   Antisense oligonucleotides: Towards clinical trials [J].
Agrawal, S .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (10) :376-387
[3]   Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors [J].
Altmann, KH ;
Fabbro, D ;
Dean, NM ;
Geiger, T ;
Monia, BP ;
Muller, M ;
Nicklin, P .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (03) :630-637
[4]  
Altmann KH, 1996, CHIMIA, V50, P168
[5]  
[Anonymous], COLD SPRING HARBOR M
[6]  
[Anonymous], THERAPEUTIC APPL OLI
[7]   2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells [J].
Baker, BF ;
Lot, SS ;
Condon, TP ;
ChengFlournoy, S ;
Lesnik, EA ;
Sasmor, HM ;
Bennett, CF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :11994-12000
[8]  
Cook P.D., 1993, ANTISENSE RES APPL, P149
[9]  
Cook P. D., 1998, ANNU REP MED CHEM, V33, P313
[10]  
COOK PD, 1991, ANTI-CANCER DRUG DES, V6, P585